These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 17230458)

  • 1. G2019S mutation in the leucine-rich repeat kinase 2 gene is not associated with multiple system atrophy.
    Ozelius LJ; Foroud T; May S; Senthil G; Sandroni P; Low PA; Reich S; Colcher A; Stern MB; Ondo WG; Jankovic J; Huang N; Tanner CM; Novak P; Gilman S; Marshall FJ; Wooten GF; Chelimsky TC; Shults CW;
    Mov Disord; 2007 Mar; 22(4):546-9. PubMed ID: 17230458
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Analysis of 14 LRRK2 mutations in Parkinson's plus syndromes and late-onset Parkinson's disease.
    Tan EK; Skipper L; Chua E; Wong MC; Pavanni R; Bonnard C; Kolatkar P; Liu JJ
    Mov Disord; 2006 Jul; 21(7):997-1001. PubMed ID: 16602113
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Lrrk2-associated parkinsonism is a major cause of disease in Northern Spain.
    González-Fernández MC; Lezcano E; Ross OA; Gómez-Esteban JC; Gómez-Busto F; Velasco F; Alvarez-Alvarez M; Rodríguez-Martínez MB; Ciordia R; Zarranz JJ; Farrer MJ; Mata IF; de Pancorbo MM
    Parkinsonism Relat Disord; 2007 Dec; 13(8):509-15. PubMed ID: 17540608
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Screening for the LRRK2 G2019S and codon-1441 mutations in a pathological series of parkinsonian syndromes and frontotemporal lobar degeneration.
    Gaig C; Ezquerra M; Martí MJ; Valldeoriola F; Muñoz E; Lladó A; Rey MJ; Cardozo A; Molinuevo JL; Tolosa E
    J Neurol Sci; 2008 Jul; 270(1-2):94-8. PubMed ID: 18353371
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Co-occurrence of sporadic parkinsonism and late-onset Alzheimer's disease in a Brazilian male with the LRRK2 p.G2019S mutation.
    Santos-Rebouças CB; Abdalla CB; Baldi FJ; Martins PA; Corrêa JC; Gonçalves AP; Cunha MS; Borges MB; Pereira JS; Laks J; Pimentel MM
    Genet Test; 2008 Dec; 12(4):471-3. PubMed ID: 19072560
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Unilateral pallidotomy in a patient with parkinsonism and G2019S LRRK2 mutation.
    Munhoz RP; Teive HA; Francisco AN; Raskin S; Rogaeva E
    Mov Disord; 2009 Apr; 24(5):791-2; author reply 792. PubMed ID: 19012346
    [No Abstract]   [Full Text] [Related]  

  • 7. Rapidly progressive multiple system atrophy in a patient carrying LRRK2 G2019S mutation.
    Carrer T; Bonato G; Sandre M; Emmi A; Campagnolo M; Musso G; Carecchio M; Parchi P; Antonini A
    Neurol Sci; 2024 Jan; 45(1):309-313. PubMed ID: 37752324
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cerebral pathological and compensatory mechanisms in the premotor phase of leucine-rich repeat kinase 2 parkinsonism.
    van Nuenen BF; Helmich RC; Ferraye M; Thaler A; Hendler T; Orr-Urtreger A; Mirelman A; Bressman S; Marder KS; Giladi N; van de Warrenburg BP; Bloem BR; Toni I;
    Brain; 2012 Dec; 135(Pt 12):3687-98. PubMed ID: 23250886
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A common leucine-rich repeat kinase 2 gene mutation in familial and sporadic Parkinson's disease in Russia.
    Illarioshkin SN; Shadrina MI; Slominsky PA; Bespalova EV; Zagorovskaya TB; Bagyeva GKh; Markova ED; Limborska SA; Ivanova-Smolenskaya IA
    Eur J Neurol; 2007 Apr; 14(4):413-7. PubMed ID: 17388990
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Atypical tauopathy in a patient with LRRK2-G2019S mutation and tremor-dominant Parkinsonism.
    Ruffmann C; Giaccone G; Canesi M; Bramerio M; Goldwurm S; Gambacorta M; Rossi G; Tagliavini F; Pezzoli G
    Neuropathol Appl Neurobiol; 2012 Jun; 38(4):382-6. PubMed ID: 21883375
    [No Abstract]   [Full Text] [Related]  

  • 11. Parkinsonism, Lrrk2 G2019S, and tau neuropathology.
    Rajput A; Dickson DW; Robinson CA; Ross OA; Dächsel JC; Lincoln SJ; Cobb SA; Rajput ML; Farrer MJ
    Neurology; 2006 Oct; 67(8):1506-8. PubMed ID: 17060589
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Subthalamic nucleus stimulation is efficacious in patients with Parkinsonism and LRRK2 mutations.
    Schüpbach M; Lohmann E; Anheim M; Lesage S; Czernecki V; Yaici S; Worbe Y; Charles P; Welter ML; Pollak P; Dürr A; Agid Y; Brice A
    Mov Disord; 2007 Jan; 22(1):119-22. PubMed ID: 17080443
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Glucocerebrosidase mutations are not found in association with LRRK2 G2019S in subjects with parkinsonism.
    Eblan MJ; Scholz S; Stubblefield B; Gutti U; Goker-Alpan O; Hruska KS; Singleton AB; Sidransky E
    Neurosci Lett; 2006 Aug; 404(1-2):163-5. PubMed ID: 16781064
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Novel LRRK2 mutations in Parkinsonism.
    Trinh J; Guella I; McKenzie M; Gustavsson EK; Szu-Tu C; Petersen MS; Rajput A; Rajput AH; McKeown M; Jeon BS; Aasly JO; Bardien S; Farrer MJ
    Parkinsonism Relat Disord; 2015 Sep; 21(9):1119-21. PubMed ID: 26213354
    [No Abstract]   [Full Text] [Related]  

  • 15. Olfactory heterogeneity in LRRK2 related Parkinsonism.
    Silveira-Moriyama L; Munhoz RP; de J Carvalho M; Raskin S; Rogaeva E; de C Aguiar P; Bressan RA; Felicio AC; Barsottini OG; Andrade LA; Chien HF; Bonifati V; Barbosa ER; Teive HA; Lees AJ
    Mov Disord; 2010 Dec; 25(16):2879-83. PubMed ID: 20818658
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical heterogeneity of the LRRK2 G2019S mutation.
    Papapetropoulos S; Singer C; Ross OA; Toft M; Johnson JL; Farrer MJ; Mash DC
    Arch Neurol; 2006 Sep; 63(9):1242-6. PubMed ID: 16966501
    [TBL] [Abstract][Full Text] [Related]  

  • 17. High prevalence of LRRK2 mutations in familial and sporadic Parkinson's disease in Portugal.
    Ferreira JJ; Guedes LC; Rosa MM; Coelho M; van Doeselaar M; Schweiger D; Di Fonzo A; Oostra BA; Sampaio C; Bonifati V
    Mov Disord; 2007 Jun; 22(8):1194-201. PubMed ID: 17469194
    [TBL] [Abstract][Full Text] [Related]  

  • 18. LRRK2 and Parkin mutations in a family with parkinsonism-Lack of genotype-phenotype correlation.
    Marras C; Klein C; Lang AE; Wakutani Y; Moreno D; Sato C; Yip E; Munhoz RP; Lohmann K; Djarmati A; Bi A; Rogaeva E
    Neurobiol Aging; 2010 Apr; 31(4):721-2. PubMed ID: 18644660
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tremor dominant parkinsonism: Clinical description and LRRK2 mutation screening.
    Clarimón J; Pagonabarraga J; Paisán-Ruíz C; Campolongo A; Pascual-Sedano B; Martí-Massó JF; Singleton AB; Kulisevsky J
    Mov Disord; 2008 Mar; 23(4):518-23. PubMed ID: 18098275
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The LRRK2 G2019S mutation in Ashkenazi Jews with Parkinson disease: is there a gender effect?
    Orr-Urtreger A; Shifrin C; Rozovski U; Rosner S; Bercovich D; Gurevich T; Yagev-More H; Bar-Shira A; Giladi N
    Neurology; 2007 Oct; 69(16):1595-602. PubMed ID: 17938369
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.